150 related articles for article (PubMed ID: 38908991)
1. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
Babar ZU
Res Social Adm Pharm; 2024 Jun; ():. PubMed ID: 38908991
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
3. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
[TBL] [Abstract][Full Text] [Related]
4. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
Front Public Health; 2021; 9():628744. PubMed ID: 33996712
[No Abstract] [Full Text] [Related]
5. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.
Nguyen TA; Knight R; Roughead EE; Brooks G; Mant A
Health Policy Plan; 2015 Mar; 30(2):267-80. PubMed ID: 24425694
[TBL] [Abstract][Full Text] [Related]
6. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
7. Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan.
Babar ZU
J Pharm Policy Pract; 2022 Feb; 15(1):9. PubMed ID: 35209945
[TBL] [Abstract][Full Text] [Related]
8. How does external reference pricing work in developing countries: evidence from Iran.
Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
[No Abstract] [Full Text] [Related]
9. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
10. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010.
Kaplan WA; Ritz LS; Vitello M; Wirtz VJ
Health Policy; 2012 Aug; 106(3):211-24. PubMed ID: 22694970
[TBL] [Abstract][Full Text] [Related]
11. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
Maniadakis N; Kourlaba G; Shen J; Holtorf A
BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
[TBL] [Abstract][Full Text] [Related]
13. Mapping the selection, availability, price and affordability of essential medicines for mental health conditions at a global level.
Todesco B; Ostuzzi G; Barbui C
Epidemiol Psychiatr Sci; 2022 Apr; 31():e22. PubMed ID: 35438063
[TBL] [Abstract][Full Text] [Related]
14. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Babar ZU; Lessing C; Mace C; Bissell K
Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
[TBL] [Abstract][Full Text] [Related]
15. Generic Medicine Pricing Policies in Europe: Current Status and Impact.
Dylst P; Simoens S
Pharmaceuticals (Basel); 2010 Mar; 3(3):471-481. PubMed ID: 27713264
[TBL] [Abstract][Full Text] [Related]
16. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
[TBL] [Abstract][Full Text] [Related]
17. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
[TBL] [Abstract][Full Text] [Related]
18. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
[TBL] [Abstract][Full Text] [Related]
19. Differences in external price referencing in Europe: a descriptive overview.
Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
